J Cancer Prev Curr Res 2017, 8(3): 00275 mutation; which is found at 10-15% of patient, and the ALK-EML4 rearrangement [3], which is found at 4-7% of patients. Several ALK tyrosine kinase inhibitors were developed in the last decade, and we hereby review the current and future ALK inhibitors and the up to date treatment of ALK-rearranged NSCLC.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.